Key facts
- This page summarizes Clare Kahn's Form 4 filing for Solid Biosciences Inc. (SLDB).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 13 Mar 2025, 16:05.
Clare Kahn - 11 Mar 2025 Form 4 Insider Report for Solid Biosciences Inc. (SLDB)
- Reporting relationship
- Director
- Issuer ticker
- SLDB
- Reported as of
- 11 Mar 2025
- Net transaction value
- +$9,924
- SEC form
- 4
- Accepted by SEC
- 13 Mar 2025, 16:05:03 UTC
- Prior SEC filing
- 13 Jun 2024
- Next SEC filing
- 13 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ David Tyronne Howton as attorney-in-fact for Clare Kahn
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Clare Kahn filed Form 4 for Solid Biosciences Inc. (SLDB) on 13 Mar 2025.
Change
- Previous filing in this sequence was filed on 13 Jun 2024.
- Current net transaction value: +$9,924.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SLDB
transaction
Common Stock
Purchase
- Transaction value
- $9,924
- Shares
- +1,860
- Change %
- +169%
- Price
- $5.34
- Shares after
- 2,960
- Date
- 11 Mar 2025
- Ownership
- Direct
* marks a reported price that did not pass the local price check.